Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Pain and Headache Reports
Erschienen in: Current Pain and Headache Reports 5/2012

01.10.2012 | Perimenstrual Headache (S Evers, Section Editor)

Treatment of Perimenstrual Migraine with Triptans: an Update

verfasst von: Barbara Casolla, Luana Lionetto, Serena Candela, Lidia D’Alonzo, Andrea Negro, Maurizio Simmaco, Paolo Martelletti

Erschienen in: Current Pain and Headache Reports | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Pure menstrual migraine (PMM) and menstrually related migraine (MRM) are difficult challenges in migraine management. Triptans are a class of highly selective serotonin receptor agonists, which interfere with the pathogenesis of migraine and are effective in relieving the associated neurovegetative symptoms. In recent years triptans have been extensively proposed for the treatment of severe, disabling, and recurrent perimenstrual migraine attacks. This review summarizes the different levels of recommendations for the use of triptans in the treatment of perimenstrual migraine. This review is also intended to offer an updated reasonable guide to physicians treating perimenstrual migraine in daily practice.
Literatur
1.
Steiner TJ, Stovner LJ, Dua T, et al. Time to act on headache disorders. J Headache Pain. 2011;12:501–3.PubMedCrossRef
2.
Steiner TJ, Birbeck GL, Jensen R, et al. The Global Campaign, World Health Organization and Lifting The Burden: collaboration in action. J Headache Pain. 2011;12:273–4.PubMedCrossRef
3.
Silberstein SD, Massiou H, Le Jeunne C, et al. Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol. 2000;96:237–42.PubMedCrossRef
4.
•• Vetvik KG, MacGregor EA, Lundqvist C et al. Self-reported menstrual migraine in the general population. J Headache Pain 2010;11:87–92. In this large survey, the authors reported the high prevalence of PMM and MRM in the general population in Norway. PubMedCrossRef
5.
Kvisvik EV, Stovner LJ, Helde G, et al. Headache and migraine during pregnancy and puerperium: the MIGRA-study. J Headache Pain. 2011;12:443–51.PubMedCrossRef
6.
•• Sacco S, Ricci S, Degan D, et al. Migraine in women: the role of hormones and their impact on vascular diseases. J Headache Pain 2012;13:177–189. This recent review highlights the importance of hormones in developing mechanisms and worsening risk factors of migraine in women. PubMedCrossRef
7.
Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261–6.PubMedCrossRef
8.
•• Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. Eur J Neurol. 2009;16:968–81. This is a cornerstone paper in the management of all forms of migraine. PubMedCrossRef
9.
Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia. 2004;24:9–160.CrossRef
10.
Calhoun AH. Menstrual migraine: update on pathophysiology and approach to therapy and management. Curr Treat Options Neurol. 2012;14:1–14.PubMedCrossRef
11.
Allais G, Castagnoli Gabellari I, Rolando S, et al. Evaluation of the use of sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea. Expert Rev Neurother. 2011;11(10):1383–7.PubMedCrossRef
12.
Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia. 2004;24:707–16.PubMedCrossRef
13.
Couturier EG, Bomhof MA, Neven AK, et al. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia. 2003;23(4):302–8.PubMedCrossRef
14.
Stewart WF, Lipton RB, Chee E, et al. Menstrual cycle and headache in a population sample of migraineurs. Neurology. 2000;55(10):1517–23.PubMedCrossRef
15.
Monteith TS, Goadsby PJ. Acute migraine therapy: new drugs and new approaches. Curr Treat Options Neurol. 2011;13:1–14.PubMedCrossRef
16.
MacGregor EA, Frith A, Ellis J, Aspinall L, et al. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology. 2006;67:2154–8.PubMedCrossRef
17.
Silberstein S, Merriam G. Sex hormones and headache 1999 (menstrual migraine). Neurology. 1999;53(4 Suppl 1):S3–13.PubMed
18.
19.
Taiwo YO, Levine JD. Prostaglandins inhibit endogenous pain control mechanisms by blocking transmission at spinal noradrenergic synapses. J Neurosci. 1988;8:1346–9.PubMed
20.
Ferreira SH, Lorenzetti BB, Correa FM. Blockade of central and peripheral generation of prostaglandins explains the antialgic effect of aspirin like drugs. Pol J Pharmacol Pharm. 1978;30:133–40.PubMed
21.
Behrman HR, Caldwell BV. Prostaglandins, thromboxanes, and leukotrienes. In: Yen SSC, Jaffe RB, editors. Reproductive endocrinology: physiology, pathophysiology and clinical management. Philadelphia: Saunders; 1986. p. 154–76.
22.
Nattero G, Allais G, De Lorenzo C, et al. Relevance of prostaglandins in true menstrual migraine. Headache. 1989;29:233–8.PubMedCrossRef
23.
Papakostas Y, Daras M, Markianos M, et al. Increased prolactin response to thyrotropin releasing hormone during migraine attacks. J Neurol Neurosurg Psychiatry. 1987;50:927–8.PubMedCrossRef
24.
Yen SSC. Prolactin in human reproduction. In: Yen SSC, Jaffe RB, editors. Reproductive endocrinology, physiology, pathophysiology and clinical management. Philadelphia: Saunders; 1986. p. 237–63.
25.
Nappi G, Martignoni E. Significance of hormonal changes in primary headache disorders. In: Olesen J, Edvinsson L, editors. Basic mechanisms of headache. New York: Elsevier; 1988. p. 277–98.
26.
Schreiber CP, Cady RK. Diagnosis of menstrual headache and an open-label study among those with previously undiagnosed menstrually related migraine to evaluate the efficacy of sumatriptan 100 mg. Clin Ther. 2007;29:2511–9.PubMedCrossRef
27.
Landy S, Savani N, Shackelford S, et al. Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. Int J Clin Pract. 2004;58:913–9.PubMedCrossRef
28.
Nett R, Landy S, Shackelford S, et al. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol. 2003;102:835–42.PubMedCrossRef
29.
Dowson AJ, Massiou H, Aurora SK. Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan. J Headache Pain. 2005;6:81–7.PubMedCrossRef
30.
Brainin M, Barnes M, Baron J-C, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces—revised recommendations 2004. Eur J Neurol. 2004;11:577–81.PubMedCrossRef
31.
Pringsheim T, Davenport WJ, Dodick D. Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology. 2008;70:1555–63.PubMedCrossRef
32.
Martin V, Cady R, Mauskop A, et al. Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat A Migraine Early) studies. Headache. 2008;48:226–35.PubMedCrossRef
33.
Nett R, Mannix LK, Mueller L, et al. Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine. Headache. 2008;48:1194–201.PubMedCrossRef
34.
Mannix LK, Loder E, Nett R, et al. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia. 2007;27:414–21.PubMedCrossRef
35.
Silberstein SD, Massiou H, McCarroll KA, et al. Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data. Headache. 2002;42:917–23.PubMedCrossRef
36.
Tuchman M, Hee A, Emeribe U, et al. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs. 2006;20:1019–26.PubMedCrossRef
37.
Allais G, Bussone G, D’Andrea G, et al. Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2011;31:144–51.PubMedCrossRef
38.
Loder E, Silberstein SD, Abu-Shakra S, et al. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache. 2004;44:120–30.PubMedCrossRef
39.
Silberstein SD, Elkind AH, Schreiber C, et al. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63:261–9.PubMedCrossRef
40.
Allais G, Bussone G, Airola G, et al. Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan. Neurol Sci. 2008;29(Suppl 1):S186–90.PubMedCrossRef
41.
MacGregor EA, Pawsey SP, Campbell JC, et al. Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: results of a new analysis of data from five previously published studies. Gend Med. 2010;7(2):88–108.PubMedCrossRef
42.
Bartolini M, Giamberardino MA, Lisotto C, et al. Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. J Headache Pain. 2012. doi:10.​1007/​s10194-012-0455-4.
43.
Massiou H, Jamin C, Hinzelin G, et al. Efficacy of oral naratriptan in the treatment of menstrually related migraine. Eur J Neurol. 2005;12(10):774–81.PubMedCrossRef
44.
Diamond ML, Cady RK, Mao L, et al. Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines. Headache. 2008;48(2):248–58.PubMedCrossRef
45.
Lionetto L, Fiorillo M, Martelletti P. Efficacy and tolerability of almotriptan in menstrual migraine: a comment. Expert Opin Pharmacother. 2011;12:2279–81.PubMedCrossRef
46.
Massiou H, Pitei D, Poole P, et al. Efficacy of eletriptan for the treatment of migraine in women with menstrually associated migraine, and in women on contraceptives or hormone replacement therapy: meta-analyses of randomized clinical trials [abstract]. Cephalalgia. 2000;20:435.CrossRef
47.
MacGregor EA, Frith A, Ellis J, et al. Predicting menstrual migraine with a home-use fertility monitor. Neurology. 2005;64:561–3.PubMedCrossRef
48.
Brandes JL, Poole A, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia. 2009;29:1133–48.PubMedCrossRef
49.
Mannix LK, Savani N, Landy S, et al. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache. 2007;47:1037–49.PubMedCrossRef
50.
Newman L, Mannix LK, Landy S, Silberstein S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized double-blind, placebo-controlled study. Headache. 2001;41:248–56.PubMedCrossRef
51.
Newman LC, Lipton RB, Lay CL, et al. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology. 1998;51:307–9.PubMedCrossRef
52.
Tuchman MM, Hee A, Emeribe U, et al. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs. 2008;22:877–86.PubMedCrossRef
53.
Marcus DA, Bernstein CD, Sullivan EA, et al. Perimenstrual eletriptan prevents menstrual migraine: an open-label study. Headache. 2010;50:551–56.PubMedCrossRef
54.
Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain. 2011;12:593–601.PubMedCrossRef
Metadaten
Titel
Treatment of Perimenstrual Migraine with Triptans: an Update
verfasst von
Barbara Casolla
Luana Lionetto
Serena Candela
Lidia D’Alonzo
Andrea Negro
Maurizio Simmaco
Paolo Martelletti
Publikationsdatum
01.10.2012
Verlag
Current Science Inc.
Erschienen in
Current Pain and Headache Reports / Ausgabe 5/2012
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-012-0280-0

Weitere Artikel der Ausgabe 5/2012

Current Pain and Headache Reports 5/2012 Zur Ausgabe

Myofascial Pain (RD Gerwin, Section editor)

Botulinum Toxin Treatment of Myofascial Pain: A Critical Review of the Literature

Myofascial Pain (RD Gerwin, Section editor)

Myofascial Pelvic Pain

Perimenstrual Headache (S Evers, Section Editor)

Transdermal Hormonal Therapy in Perimenstrual Migraine: Why, When and How?

Perimenstrual Headache (S Evers, Section Editor)

Perimenstrual Headache in Adolescence

Fibromyalgia (MFP Peres, Section editor)

The Effects of Meditation-Based Interventions on the Treatment of Fibromyalgia

Perimenstrual Headache (S Evers, Section Editor)

Hormonal Contraception and Migraine: Clinical Considerations

Neu im Fachgebiet AINS

Blutdrucksenkung schon im Rettungswagen bei akutem Schlaganfall?

31.05.2024 Apoplex Nachrichten

Der optimale Ansatz für die Blutdruckkontrolle bei Patientinnen und Patienten mit akutem Schlaganfall ist noch nicht gefunden. Ob sich eine frühzeitige Therapie der Hypertonie noch während des Transports in die Klinik lohnt, hat jetzt eine Studie aus China untersucht.

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

29.05.2024 Reanimation im Kindesalter Nachrichten

Laut einer Studie aus den USA und Kanada scheint es bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise